RXi Pharmaceuticals Corporation , a recognized leader in RNAi-based therapeutics, announced that as part of its collaboration with miRagen Therapeutics, Inc., positive data were generated demonstrating that RXi SD-rxRNA technology can be used vitro, and in particular to improve the activity of a microRNA of great interest to miRagen.‘MicroRNA sequences that mimic the native therapeutic approaches require special delivery,’ said William S. Marshall, Ph., President and CEO of miRagen Therapeutics. ‘We are pleased that the technology of self-distribution RXi demonstrates compatibility with microRNA sequences from our portfolio.’
The parties have successfully applied RXi proprietary sd-rxRNA technology to create microRNA mimics or copies of artificial microRNAs. In particular, they have demonstrated the efficacy in down-regulation of a reporter gene whose expression is controlled by microRNAs in cell culture systems developed according to the type miRagen. These data will be presented in a poster at the Keystone Symposia future microRNA and non-coding RNAs and Cancer meeting 11 to 16 February 2011 and will be available on the website after the conference RXi.
The State Plan is designed to streamline the functions of government, reduce costs and increase efficiency through the effective use of existing resources. Objectives and recommendations include a commitment to research and development of the system while minimizing the social stigma and improve the detection, diagnosis, treatment and care for individuals and families affected by the disease. These include the restoration and improvement of the nursing home system in California and the community, as well as caregiver support and training of professionals.
Adequate training and support to families can help prevent the request for public funding, high-cost settings such as hospitals, emergency room and nursing homes.